Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Moderna (MRNA) stock drops even after beating Q2 2025 forecasts, as it lowered the top end of the revenue outlook due to ...

Moderna surpassed Wall Street sales predictions due to strong Spring COVID booster demand but lowered its 2025 sales forecast, causing a premarket share decline. Despite a 41% revenue drop to $142 ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

Despite the irresponsible “political” noise surrounding the matter, vaccines remain an important step for parents to take in keeping their children as healthy and safe as possible. For those with ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

As federal vaccine policy shifts under US health secretary Robert F. Kennedy Jr., lawmakers are looking to give state-level ...